Bordeaux, France-based Implanet, has entered into exclusive negotiations to divest its MADISON™ total knee prosthesis business to Décines-Charpieu, France-based SERF (Société d’Etude, de Recherche et de Fabrication).
Implanet to Sell Knee Business to SERF
1 min read Premium comments
Secondary#implanet#menixgroup#serf
SERF is part of Lyon, France-based Menix Group, a holding company for brands in orthopedics, dental implants, and craniomaxillofacial surgery.
Implanet is a medical technology company that manufactures implants for orthopedic surgery. The company’s two areas of focus were solutions for the treatment of spinal pathologies and its MADISON implant. In May of this year, the company announced its intention to sell its MADISON total knee implant to focus on its spine business. For OTW’s coverage of the announcement, see “Implanet to Sell MADISON Total Knee Implant.”
This year, Implanet also announced its acquisition of Avignon, France-based Orthopaedic & Spine Development (OSD), a company dedicated to spine surgery implants. For OTW’s coverage of the acquisition, see “Implanet Buys Spine Surgery Company.”
Implanet CEO Ludovic Lastennet commented, “Implanet is very pleased to announce the initiation of exclusive negotiations with SERF regarding the divestment of its knee activity. This operation, which follows discussions held with the Menix Group since May 2020, represents the next step, after the acquisition of OSD, in the execution of our strategy enabling us to refocus on our spine business and accelerate our growth on this segment.”
Lastennet continued, “Following this operation, Implanet will be 100% focused on the treatment of spinal disorders. Furthermore, thanks to this divestment, we will have additional financial resources to intensify our growth and make Implanet a powerful player in the field of spinal disorders.”
The acquisition will also allow SERF to strengthen its influence in the knee segment of the orthopedic industry. Menix executives commented in the press release that the acquisition reaffirms the company’s intention of strengthening its position in the knee disorder segment of orthopedics.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.